Alexion Pharmaceuticals (ALXN) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (24.1 million) in Alexion Pharmaceuticals (ALXN). On Wednesday, The value of composite uptick trades was $38.59 million, whereas, the value of composite downtick trades was $62.69 million and the ratio between the two was 0.62, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $26.42 million. $2.79 million was the block trade value on upticks. The ratio between the two was clearly in favor of the bears at 0.11. The negative money flow of ($23.63 million) shows selling on strength. Alexion Pharmaceuticals (ALXN) gained $2.77 intraday at $126.93 and registrered 2.23% for the week.
Also, RBC Capital initiates coverage on Alexion Pharmaceuticals (NASDAQ:ALXN) The brokerage firm has issued a Outperform rating on the shares. The rating by the firm was issued on July 13, 2016.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $124.15 and $123.96 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $128.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $126.93, notching a gain of 2.23% for the day. The total traded volume was 1,817,215 . The stock had closed at $124.16 on the previous day.
The stock has recorded a 20-day Moving Average of 4.92% and the 50-Day Moving Average is 4.75%. In a related news, The Securities and Exchange Commission has divulged that Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, had unloaded 918 shares at an average price of $135.72 in a transaction dated on June 13, 2016. The total value of the transaction was worth $124,591.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.